Position in INKT
as of Jun 30, 2026
· filed Sep 2, 2026
Position Value
$180,493
+$161,599 QoQ
Shares Held
15,440
+642.0% QoQ
Ownership
0.303%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 27 holders
Holding Since
Jun 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INKT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $6,150,758,606 across 435 Biotechnology names. INKT ranks #323 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ONC |
BeOne Medicines Ltd.
|
1,425,517 | $406,229,578 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
3,760,028 | $280,046,885 | |
| 3 | INSM |
INSMED Inc
|
2,556,973 | $272,624,460 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
507,233 | $272,358,759 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
510,430 | $253,545,893 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,006,676 | $242,578,715 | |
| 7 | MANE |
Veradermics, Inc
|
1,877,775 | $230,853,658 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,576,261 | $197,343,876 |
All Filings in INKT
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $180,493 | 15,440 | Shares | Defined | 2026-09-02 | |
| 2024-03-31 | $18,894 | 20,809 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $45,090 | 42,141 | Shares | Defined | 2024-02-14 | |
| 2023-06-30 | $107,200 | 51,048 | Shares | Defined | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||